The Eph family member EPHA2 has recently been proposed as a negative prognostic factor in triple-negative breast cancer (TNBC) patients; moreover, EPHA2 may act as a precision therapeutic target for this challenging condition [181]. This evidence concerns the gene EPHA2 and triple-negative breast carcinoma.